Relevant bibliographies by topics / Target therapies

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Target therapies'

Author: Grafiati
Published: 28 January 2023
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Target therapies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Target therapies"

1

Lazzari, Ludovico, Marcella De Paolis, Daniella Bovelli, and Enrico Boschetti. "Target therapies-induced Cardiotoxicity." European Oncology & Haematology 09, no. 01 (2013): 56. http://dx.doi.org/10.17925/eoh.2013.09.1.56.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

&NA;. "Rheumatoid arthritis therapies target TNF." Inpharma Weekly &NA;, no. 1173 (1999): 2. http://dx.doi.org/10.2165/00128413-199911730-00002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bearz, A., M. Berretta, A. Lleshi, and U. Tirelli. "Target Therapies in Lung Cancer." Journal of Biomedicine and Biotechnology 2011 (2011): 1–5. http://dx.doi.org/10.1155/2011/921231.

Full text
Abstract:
Targeting intracellular signaling molecules is an attractive approach for treatment of malignancies. In particular lung cancer has reached a plateau regarding overall survival, and target therapies could offer the possibility to improve patients' outcome beyond cytotoxic activity. The goal for target therapies is to identify agents that target tumor-specific molecules, thus sparing normal tissues; those molecules are called biomarkers, and their identification is recommended because it has a predictive value, for example, provides information on outcome with regard to a specific treatment. The
APA, Harvard, Vancouver, ISO, and other styles
4

Silvestris, Nicola, Antonio Gnoni, Anna Brunetti, et al. "Target Therapies in Pancreatic Carcinoma." Current Medicinal Chemistry 21, no. 8 (2014): 948–65. http://dx.doi.org/10.2174/09298673113209990238.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hampton, Tracy. "Novel Therapies Target Myasthenia Gravis." JAMA 298, no. 2 (2007): 163. http://dx.doi.org/10.1001/jama.298.2.163.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Meijer, G. A., and J. J. Oudejans. "Targeted Therapies; Who Detects the Target?" Analytical Cellular Pathology 27, no. 3 (2005): 165–67. http://dx.doi.org/10.1155/2005/235650.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Wakabayashi, Hiroshi. "Molecular target therapies in rheumatic diseases." Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 126, no. 3 (2014): 227–30. http://dx.doi.org/10.4044/joma.126.227.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Robson, Andrew. "Three different therapies to target PCSK9." Nature Reviews Cardiology 18, no. 8 (2021): 541. http://dx.doi.org/10.1038/s41569-021-00581-w.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hirsch, Etienne. "Parkinson's disease: A target for therapies?" Journal of the Neurological Sciences 429 (October 2021): 118011. http://dx.doi.org/10.1016/j.jns.2021.118011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gillis, David. "Two Novel Therapies Target Cellular Microenvironment." Oncology Times 24, no. 2 (2002): 38. http://dx.doi.org/10.1097/01.cot.0000294265.17109.36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Target therapies"

1

Holt, Sandra. "Fatty acid amide hydrolase - A target for anti-inflammatory therapies?" Doctoral thesis, Umeå universitet, Farmakologi, 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-504.

Full text
Abstract:
Anti-inflammatory drugs are a widely used class of therapeutic agents, but the use of non-steroidal anti-inflammatory drugs (NSAID) is hampered by their gastrointestinal side-effects. Recent reports that cyclooxygenase-2 inhibitors may cause cardiovascular events underline the importance of identifying new therapeutic strategies for the treatment of inflammation. One such target could be agents modifying the endogenous cannabinoid (endocannabinoid) system, since there is evidence that this system plays a role in our natural defence against inflammation. The levels of the endocannabinoid ananda
APA, Harvard, Vancouver, ISO, and other styles
2

Di, Stefano Anna Luisa. "Molecular markers of gliomas : implications for diagnosis and new target therapies." Thesis, Paris 6, 2017. http://www.theses.fr/2017PA066015.

Full text
Abstract:
Le travail de thèse est dédié à la caractérisation de fusions spécifiques oncogéniques entre les gènes FGFR et TACC dans les gliomes. Nous avons analysé 907 gliomes pour la présence du gène de fusion FGFR3-TACC3. Nous avons montré que les fusions FGFR3-TACC3 ne touchent que les gliomes IDH wild-type (3%), sont mutuellement exclusives avec l'amplification de EGFR et avec la forme tronquée EGFRvIII et inversement, sont associées à l'amplification de CDK4 et de MDM2 et à la délétion du 10q. Les fusions FGFR3-TACC3 sont associées à une expression intense et diffuse de FGFR3 en immunohistochimie (I
APA, Harvard, Vancouver, ISO, and other styles
3

DI, STEFANO ANNA LUISA. "MOLECULAR MARKERS OF GLIOMAS Implications for diagnosis and new target therapies." Doctoral thesis, Università degli studi di Pavia, 2017. http://hdl.handle.net/11571/1203374.

Full text
Abstract:
The 2016 WHO classification of gliomas integrates molecular alterations (ie IDH mutations, and 1p19q codeletion) to histological features, defining distinct histo-molecular entities: IDH wild-type gliomas (mostly glioblastomas), and IDH mutated gliomas, divided according to 1p19q status into astrocytomas (1p19q intact) and oligodendrogliomas (1p19q codeleted). The first part of the manuscript is a contribution to molecular classification based on TERT promoter mutational status. We also contributed to GWAS analysis, and investigated the association between the risk loci and specific molecular
APA, Harvard, Vancouver, ISO, and other styles
4

Han, Yanyan. "Functional characterization of FMNL1 as potential target for novel anti-tumor therapies." Diss., lmu, 2010. http://nbn-resolving.de/urn:nbn:de:bvb:19-112968.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Zincke, Fabian. "Biomarker based therapies in high risk cancer patients - MACC1 as molecular target." Doctoral thesis, Humboldt-Universität zu Berlin, 2020. http://dx.doi.org/10.18452/21021.

Full text
Abstract:
Das metastasierende kolorektale Karzinom stellt eine große Herausforderung in der Krebstherapie dar. Verlässliche und effiziente Biomarker zur Prognose des Krankheitsverlaufes oder der Therapieantwort (Prädiktion) sind rar. Metastasis-associated in colon cancer 1 (MACC1) ist ein prognostischer, prädiktiver und kausaler Biomarker für verschiedene Tumorentitäten. Durch die Induzierung von Zielgenen, wie z.B. MET, beeinflusst es Signalwege wie MEK/ERK und AKT/β-catenin und fördert so Zellproliferation und -motilität sowie Tumorprogression und Metastasierung in vivo. Diese Arbeit sollte neue Strat
APA, Harvard, Vancouver, ISO, and other styles
6

Dussol, Manon. "Delta-opioïd receptor : a potential new target for migraine and headache therapies." Electronic Thesis or Diss., Université Clermont Auvergne (2021-...), 2023. http://theses.bu.uca.fr/nondiff/2023UCFA0142_DUSSOL.pdf.

Full text
Abstract:
Objectif : La migraine est un trouble hautement invalidant, pour lequel les traitements disponibles manquent d'efficacité chez de nombreux patients, soulignant ainsi la nécessité de nouveaux traitements. Le récepteur opioïde delta (DOR) est devenu une cible thérapeutique prometteuse pour la migraine. Chez la souris, les agonistes du DOR inhibent l'allodynie associée à la migraine. Cependant, des différences d'espèces (rat vs souris), régionales (trijumeau vs spinal) et de mécanisme (périphérique vs central) existent dans la contribution du DOR dans la régulation des céphalées de type migraine.
APA, Harvard, Vancouver, ISO, and other styles
7

ULTIMO, Simona. "Inhibition of the PI3K/Akt/mTOR signaling pathway as a therapeutic target for Acute Lymphoblastic Leukemia." Doctoral thesis, Università degli studi di Ferrara, 2018. http://hdl.handle.net/11392/2487845.

Full text
Abstract:
Acute Lymphoblastic Leukemia (ALL) is a malignant disorder characterized by the abnormal clonal proliferation of B-cell progenitors (B-ALL) or immature stage thymocytes (T-ALL). Constitutive activation of the PI3K/Akt/mTOR network is a common feature of B- and T-ALL, influencing cell growth and survival. The PI3K/Akt/mTOR inhibitors are currently being developed for clinical use either as single agents or in combination with conventional chemotherapy for T-ALL patient treatment. In this study it has been investigated the effects of a panel of PI3K/Akt/mTOR inhibitors on healthy human CD4+ T-c
APA, Harvard, Vancouver, ISO, and other styles
8

Ito, Koichi. "Galectin-1 as a Potent Target for Cancer Therapy: Role in the Tumour Microenvironment." Thesis, Griffith University, 2013. http://hdl.handle.net/10072/367472.

Full text
Abstract:
Despite many new and significant discoveries made in cancer research in the last few decades, only limited improvements in overall responses to treatment have occurred. The frustrating gaps between the scientific evidence and minor advances in clinical outcomes as well as unacceptable treatment failure must be overcome by improving current cancer therapies and developing more effective anti-cancer strategies. The term “tumour heterogeneity” refers to the formation of a tumour containing areas with distinguishable phenotypic features within its microenvironment. The realisation that a tumour ti
APA, Harvard, Vancouver, ISO, and other styles
9

Kyle, Fiona. "LRH-1 as a target for the development of new breast cancer therapies." Thesis, Imperial College London, 2014. http://hdl.handle.net/10044/1/55285.

Full text
Abstract:
Estrogen drives the growth and development of estrogen receptor alpha (ERα) positive breast cancer and ERα is the target for hormonal therapies that inhibit its activity. A substantial proportion of patients become resistant to these therapies, demonstrating a need for new therapies. Gene expression microarray studies have been performed with a view to identifying potential novel therapeutic targets, biomarkers or forming the basis of identifying a molecular signature for endocrine resistance. These studies have identified candidate genes whose expression is altered in models of endocrine resi
APA, Harvard, Vancouver, ISO, and other styles
10

Cunniff, Brian. "Mitochondrial structure and function as a therapeutic target in malignant mesothelioma." ScholarWorks @ UVM, 2014. http://scholarworks.uvm.edu/graddis/249.

Full text
Abstract:
Malignant mesothelioma (MM) is a rare tumor associated with occupational exposure to asbestos with no effective treatment regime. Evaluation of mitochondrial function in human MM cell lines revealed a common tumor phenotype: in comparison to immortalized or primary human mesothelial cells, MM tumor cells displayed a more oxidized mitochondrial environment, increased expression of mitochondrial antioxidant enzymes, and altered mitochondrial metabolism. Earlier work by our laboratory indicated that increases in mitochondrial reactive oxygen species (mROS) in MM cell lines supports expression of
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Target therapies"

1

Corporation, Market Intelligence Research, and Frost & Sullivan., eds. Autoimmune disease: Therapeutic markets : new therapies target causes, not symptoms. Market Intelligence, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dzau, Victor J., and Gabor M. Rubanyi. The endothelium in clinical practice: Source and target of novel therapies. M. Dekker, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Albert, Jeffrey S., and Michael W. Wood, eds. Targets and Emerging Therapies for Schizophrenia. John Wiley & Sons, Inc., 2012. http://dx.doi.org/10.1002/9781118309421.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Albert, Jeffrey S., and Michael W. Wood. Targets and emerging therapies for schizophrenia. John Wiley & Sons, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Los, Marek, and Spencer B. Gibson, eds. Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases. Springer-Verlag, 2005. http://dx.doi.org/10.1007/b102187.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Paleari, Laura, ed. Cancer Prevention with Molecular Target Therapies. MDPI, 2023. http://dx.doi.org/10.3390/books978-3-0365-7926-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Paleari, Laura, ed. Cancer Prevention with Molecular Target Therapies 3.0. MDPI, 2023. http://dx.doi.org/10.3390/books978-3-0365-7908-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Paleari, Laura, ed. Cancer Prevention with Molecular Target Therapies 4.0. MDPI, 2024. http://dx.doi.org/10.3390/books978-3-7258-1951-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hillis, Argye E., and Jean-Claude Baron, eds. The Ischemic Penumbra: Still the Target for Stroke Therapies? Frontiers Media SA, 2015. http://dx.doi.org/10.3389/978-2-88919-635-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Drouin-Ouellet, Janelle, and Roger A. Barker. Disease-Modifying Therapies in Neurodegenerative Disorders. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190233563.003.0016.

Full text
Abstract:
The recent identification of the genetic basis of many neurodegenerative disorders (NDDs), coupled with a greater understanding of their pathophysiology, has enabled better therapeutic strategies to be identified and tried. This includes approaches that target critical specific nodes in the disease pathways, for example, agents that modulate levels of mutant huntingtin in Huntington’s disease. In addition to these highly specific targeted therapies, there is also a growing realization that more generic lifestyle therapies influencing whole brain health may also have merit in treating these con
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Target therapies"

1

Kefas, Benjamin, and Benjamin W. Purow. "microRNA: A Potential Therapy Able to Target Multiple Cancer Pathways." In Targeted Therapies. Humana Press, 2011. http://dx.doi.org/10.1007/978-1-60761-478-4_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Cortot, Alexis B., and Pasi A. Jänne. "Resistance to Targeted Therapies As a Result of Mutation(s) in the Target." In Targeted Therapies. Humana Press, 2011. http://dx.doi.org/10.1007/978-1-60761-478-4_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yamada, Yuma, Fumika Kubota, Rina Naganawa, Satrialdi, and Hideyoshi Harashima. "Cancer Photo Therapies that Target Mitochondria." In Nanomedicine and Nanotoxicology. Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-97-5288-1_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wang, Haichao, Wei Li, Richard Goldstein, Kevin J. Tracey, and Andrew E. Sama. "HMGB1 as a Potential Therapeutic Target." In Sepsis: New Insights, New Therapies. John Wiley & Sons, Ltd, 2008. http://dx.doi.org/10.1002/9780470059593.ch6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Myall, Nathaniel J., and Sukhmani K. Padda. "BRAF: Novel Therapies for an Emerging Target." In Targeted Therapies for Lung Cancer. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-17832-1_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Siemann, Dietmar W. "Tumor Vasculature: a Target for Anticancer Therapies." In Vascular-Targeted Therapies in Oncology. John Wiley & Sons, Ltd, 2006. http://dx.doi.org/10.1002/0470035439.ch1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Michaelis, Uwe, and Michael Teifel. "Cationic Lipid Complexes to Target Tumor Endothelium." In Vascular-Targeted Therapies in Oncology. John Wiley & Sons, Ltd, 2006. http://dx.doi.org/10.1002/0470035439.ch13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Shay, Jerry W. "Telomerase as a Target for Cancer Therapeutics." In Gene-Based Therapies for Cancer. Springer New York, 2010. http://dx.doi.org/10.1007/978-1-4419-6102-0_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hajishengallis, George, Tetsuhiro Kajikawa, Evlambia Hajishengallis, et al. "Complement C3 as a Target of Host Modulation in Periodontitis." In Emerging Therapies in Periodontics. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-42990-4_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Dutzan, Nicolas, Loreto Abusleme, and Niki Moutsopoulos. "The IL-17/Th17 Axis as a Therapeutic Target in Periodontitis." In Emerging Therapies in Periodontics. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-42990-4_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Target therapies"

1

Langley, Andrew, Allison Sweeney, Christopher Nguyen, Skye Edwards, Deeksha Sankepalle, and Srivalleesha Mallidi. "Non-invasive simultaneous assessment of therapy-induced tumor microenvironmental changes in collagen and vasculature with photoacoustic imaging." In Optical Molecular Probes, Imaging and Drug Delivery. Optica Publishing Group, 2025. https://doi.org/10.1364/omp.2025.om5e.2.

Full text
Abstract:
The tumor microenvironment (TME) is critical for tumor cell survival and metastasis, comprising both cellular (immune and stromal cells) and non-cellular (extracellular matrix, ECM) components. Collagen within the ECM, produced by cancer-associated fibroblasts, fosters aggressive tumor phenotypes and confers resistance to chemotherapy. To enhance the efficacy of cancer therapies, various innovative strategies are being developed to normalize or target tumor collagen. We have previously demonstrated that photodynamic therapy (PDT) at low doses, termed photodynamic priming (PDP), can degrade col
APA, Harvard, Vancouver, ISO, and other styles
2

Pierotti, Marco A. "Abstract CN1-1: Target mutation: The dark side of targeted therapies." In Abstracts: AACR International Conference on Translational Cancer Medicine--; Mar 21–24, 2010; Amsterdam, The Netherlands. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1078-0432.tcme10-cn1-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yang, Yu-an, Howard Yang, Ying Hu, et al. "Abstract 1846: Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis therapies to target breast cancer metastasis." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-1846.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mojarrad, Mehran. "Nanotechnology Based Cancer Therapies." In ASME 2007 2nd Frontiers in Biomedical Devices Conference. ASMEDC, 2007. http://dx.doi.org/10.1115/biomed2007-38034.

Full text
Abstract:
By all accounts cancer remains the leading cause of death for humans of age less than 85 years old. This is partly because of the fact that there has been success in addressing other competing diseases such as cardiovascular leading to an overall drop in the rate of such disease where as after four decades of research success in cancer therapy remains limited. This places a greater demand on developing new therapies to treat cancer. With recent advances in nanotechnology field as applied in medicine there are new opportunities to detect, more effectively target and treat cancer and monitor the
APA, Harvard, Vancouver, ISO, and other styles
5

Fernandes, Caio J., Carlos Jardim, Bruno A. Dias, et al. "The Role Of Target-Therapies In Schistosomiasis-Associated Pulmonary Arterial Hypertension." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a5918.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sarkar, Saugata, and Marissa Nichole Rylander. "Treatment Planning Model for Nanotube-Mediated Laser Cancer Therapy." In ASME 2008 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2008. http://dx.doi.org/10.1115/sbc2008-192997.

Full text
Abstract:
The goal of the project is to develop an effective treatment planning computational tool for nanotube-mediated laser therapy that maximizes tumor destruction and minimizes tumor recurrence. Laser therapies can provide a minimally invasive treatment alternative to surgical resection of tumors. However, the effectiveness of these therapies is limited due to nonspecific heating of target tissue and diffusion limited thermal deposition which often leads to healthy tissue injury and extended treatment durations. These therapies can be further compromised due to induction of molecular chaperones cal
APA, Harvard, Vancouver, ISO, and other styles
7

Claret, Francois X., Thuy Vu, Terry J. Shackleford, et al. "Abstract 1825: Jab1/Csn5 a new target in the resistant mechanism to HER2-targeted therapies for breast cancer." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-1825.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sarkar, Saugata, Amy Lutkus, James Mahaney, et al. "Carbon Nanohorns as Photochemical and Photothermal Agents." In ASME 2009 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2009. http://dx.doi.org/10.1115/sbc2009-206796.

Full text
Abstract:
Laser therapies based on photochemical or photothermal mechanisms can provide a minimally invasive and potentially more effective treatment alternative to conventional surgical resection procedures by delivering prescribed optical/thermal doses to a targeted tissue volume with minimal damage to intervening and surrounding tissues. However laser therapy effectiveness is limited due to nonspecific excitation/heating of target tissue which often results in healthy tissue injury. Nanostructures targeted to tumor cells and utilized in combination with laser excitation can enhance treatment effectiv
APA, Harvard, Vancouver, ISO, and other styles
9

Campbell, Timothy B., and Emmanuelle Passegué. "Abstract A38: Remodeling of the malignant bone marrow niche represents a therapeutic target." In Abstracts: AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; September 20-23, 2014; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1557-3265.hemmal14-a38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Goverdhan, Aarthi, Heng-Huan Lee, Ondrej Havranek, Richard Eric Davis, and Mien-Chie Hung. "Abstract 13: PRMT1 as a therapeutic target in diffuse large B-cell lymphoma." In Abstracts: Second AACR Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; May 6-9, 2017; Boston, MA. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1557-3265.hemmal17-13.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Target therapies"

1

Shujaa, Asaad Suliman, and Qasem Almulihi. The efficacy and safety of ketamine in treating refractory and super-refractory status epilepticus in pediatric and adult populations, A systemic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.11.0011.

Full text
Abstract:
Review question / Objective: This study is to assess the efficacy and safety of ketamine in treating refractory and super-refractory status epilepticus in pediatric and adult populations. Rationale: Refractory status epilepticus (RSE) is either generalized or complex partial status epilepticus (SE) that fails to respond to first and second-line therapies. Super refractory status epilepticus (SRSE) is SE that remains unresponsive despite 24 hours of therapy with general anesthesia [1, 2]. Both RSE and SRSE pose significant challenges for the managing intensivist. There exists a race against tim
APA, Harvard, Vancouver, ISO, and other styles
2

Vail, Neal. Targeted Therapies for Myeloma and Metastatic Bone Cancers. Defense Technical Information Center, 2008. http://dx.doi.org/10.21236/ada485553.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Vail, Neal. Targeted Therapies for Myeloma and Metastatic Bone Cancers. Defense Technical Information Center, 2006. http://dx.doi.org/10.21236/ada454700.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rossini, J. G., and Neal Vail. Targeted Therapies For Myeloma and Metastatic Bone Cancers. Defense Technical Information Center, 2009. http://dx.doi.org/10.21236/ada535238.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Malkin, David, and Diana Merino. Molecular Targeted Therapies of Childhood Choroid Plexus Carcinoma. Defense Technical Information Center, 2013. http://dx.doi.org/10.21236/ada592041.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Vail, Neal. Targeted Therapies for Myeloma and Metastatic Bone Cancers. Defense Technical Information Center, 2007. http://dx.doi.org/10.21236/ada467829.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Malkin, David. Molecular Targeted Therapies of Childhood Choroid Plexus Carcinoma. Defense Technical Information Center, 2011. http://dx.doi.org/10.21236/ada555024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Vail, Neal. Targeted Therapies for Myeloma and Metastatic Bone Cancers. Defense Technical Information Center, 2010. http://dx.doi.org/10.21236/ada555410.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Agrafiotis, Apostolos, Mariana Brandão, Thierry Berghmans, Valérie Durieux, and Christiane Jungels. Immunotherapy and targeted therapies efficacy in thymic epithelial tumors: a systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.8.0080.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Htet, Htet, Jwala Rebecca James Anaghan, Heethal Jaiprakash, Igor Nikolayevich Lezhitsa, and Renu Agarwal. Efficacy and safety of molecular-targeted therapies in nasopharyngeal carcinoma: A network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.8.0024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Target therapies' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography